OraSure Technologies (OSUR) Upgraded to “Buy” at ValuEngine

OraSure Technologies (NASDAQ:OSUR) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

A number of other research firms have also issued reports on OSUR. Stephens lowered shares of OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. TheStreet upgraded shares of OraSure Technologies from a “c+” rating to a “b” rating in a report on Thursday, August 9th. BidaskClub lowered shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. Finally, Raymond James restated a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.50.

Shares of OSUR stock traded down $1.86 during trading hours on Tuesday, reaching $12.86. 25,801 shares of the stock traded hands, compared to its average volume of 533,192. OraSure Technologies has a 1-year low of $13.21 and a 1-year high of $22.22. The firm has a market capitalization of $883.96 million, a P/E ratio of 25.27, a P/E/G ratio of 3.40 and a beta of 1.52.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.02. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The business had revenue of $45.90 million for the quarter, compared to analyst estimates of $44.50 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. Equities research analysts predict that OraSure Technologies will post 0.34 EPS for the current fiscal year.

In other OraSure Technologies news, Director Charles W. Patrick sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $16.29, for a total value of $130,320.00. Following the transaction, the director now owns 54,298 shares in the company, valued at approximately $884,514.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 2.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in OSUR. Fred Alger Management Inc. increased its stake in OraSure Technologies by 62.8% in the 2nd quarter. Fred Alger Management Inc. now owns 2,695,239 shares of the medical instruments supplier’s stock valued at $44,391,000 after buying an additional 1,040,166 shares during the period. BlackRock Inc. increased its stake in OraSure Technologies by 10.6% in the 2nd quarter. BlackRock Inc. now owns 8,480,830 shares of the medical instruments supplier’s stock valued at $139,679,000 after buying an additional 810,442 shares during the period. Systematic Financial Management LP increased its stake in OraSure Technologies by 520.8% in the 3rd quarter. Systematic Financial Management LP now owns 499,254 shares of the medical instruments supplier’s stock valued at $7,713,000 after buying an additional 418,833 shares during the period. Casdin Capital LLC increased its stake in OraSure Technologies by 166.7% in the 2nd quarter. Casdin Capital LLC now owns 640,000 shares of the medical instruments supplier’s stock valued at $10,541,000 after buying an additional 400,000 shares during the period. Finally, Emerald Advisers Inc. PA increased its stake in shares of OraSure Technologies by 49.1% during the 2nd quarter. Emerald Advisers Inc. PA now owns 1,007,294 shares of the medical instruments supplier’s stock worth $16,590,000 after purchasing an additional 331,922 shares during the last quarter. Hedge funds and other institutional investors own 92.00% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Article: What are earnings reports?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply